title: Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?
abstract: Severe alpha(1)-antitrypsin (AAT) deficiency is an inherited disorder that leads to the development of emphysema in smokers at a relatively young age; most are disabled in their forties. Emphysema is caused by the protease-antiprotease imbalance when smoking-induced release of neutrophil elastase in the lung is inadequately inhibited by the deficient levels of AAT, the major inhibitor of neutrophil elastase. This protease-antiprotease imbalance leads to proteolytic damage to lung connective tissue (primarily elastic fibers), and the development of panacinar emphysema. AAT replacement therapy, most often applied by weekly intravenous infusions of AAT purified from human plasma, has been used to partially correct the biochemical defect and raise the serum AAT level above a theoretically protective threshold level of 0.8 g/L. A randomized controlled clinical trial was not considered feasible when purified antitrypsin was released for clinical use. However, AAT replacement therapy has not yet been proven to be clinically effective in reducing the progression of disease in AAT-deficient patients. There was a suggestion of a slower progression of emphysema by computed tomography (CT) scan in a small randomized trial. Two nonrandomized studies comparing AAT-deficient patients already receiving replacement therapy with those not receiving it, and a retrospective study evaluating a decline in FEV(1) before and after replacement therapy, suggested a possible benefit for selected patients. Because of the lack of definitive proof of the clinical effectiveness of AAT replacement therapy and its cost, we recommend reserving AAT replacement therapy for deficient patients with impaired FEV(1) (35-65% of predicted value), who have quit smoking and are on optimal medical therapy but continue to show a rapid decline in FEV(1) after a period of observation of at least 18 months. A randomized placebo-controlled trial using CT scan as the primary outcome measure is required. Screening for AAT deficiency is recommended in patients with chronic irreversible airflow obstruction with atypical features such as early onset of disease or disability in their forties or fifties, or positive family history, and in immediate family members of patients with AAT deficiency.
authors.affiliation: Respiratory Division, University of British Columbia, 2775 Heather Street, Vancouver, V5Z 3J5, British Columbia, Canada. rtabboud@interchange.ubc.ca
authors.forename: Raja T
authors.initials: RT
authors.lastname: Abboud
authors.forename: Gordon T
authors.initials: GT
authors.lastname: Ford
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Chapman
mesh_terms: D005820:Genetic Testing; D006801:Humans; D007262:Infusions, Intravenous; D011656:Pulmonary Emphysema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014361:Trypsin Inhibitors / Q000627:therapeutic use*; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use*; D019896:alpha 1-Antitrypsin Deficiency / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology
chemical_list: D014361:Trypsin Inhibitors; D000515:alpha 1-Antitrypsin